论文部分内容阅读
目的探讨盐酸替罗非班对非ST段抬高型急性心肌梗死(NSTEAMI)患者早期介入治疗的疗效及安全性。方法选择NSTEAMI患者100例,随机分为替罗非班试验组(n=50)和对照组(n=50),均于入选后72h内接受早期PCI治疗。结果试验组PCI术前病变血管前向血流达TIMI3级的比率高于对照组,其差异有统计学意义(P<0.05)。结论 NSTEAMI患者早期介入治疗术前应用替罗非班安全有效。
Objective To investigate the efficacy and safety of tirofiban hydrochloride for early interventional therapy in patients with non-ST-elevation acute myocardial infarction (NSTEAMI). Methods One hundred patients with NSTEAMI were randomly divided into Tirofiban test group (n = 50) and control group (n = 50). All patients were treated with early PCI within 72 hours after their enrollment. Results The ratio of TIMI3 grade in blood flow before PCI in experimental group was higher than that in control group, the difference was statistically significant (P <0.05). Conclusions Early interventional therapy in patients with NSTEAMI is safe and effective before tirofiban.